Anvisa Approves Five More Pens for Diabetes and Obesity; Total Reaches 20 in 2026
The new registrations are for liraglutide and semaglutide, but there is still no launch date or set pharmacy price.
Translated from the Portuguese original by the Panorama newsroom. Read in Portuguese
Summary written by the Panorama newsroom from the sources listed below. Facts are attributed to the original publications.
Anvisa, Brazil's health regulator, approved five new pens based on liraglutide and semaglutide, used to treat diabetes and obesity. The registrations were published in Thursday's (29) Diário Oficial da União and raise to 20 the number of pens in this class approved by the agency in 2026, g1 reported.
Three products are indicated for diabetes: Aribet (liraglutide), from Farma Vision, made by India's Biocon; Embeltah (semaglutide), from Dr. Reddy's; and Sevema (semaglutide), from Aché, both made by OneSource Specialty. For weight control, Lyrza and Wylovol, both liraglutide and also from Farma Vision, were cleared.
The drugs belong to the class of GLP-1 receptor agonists, which mimic a hormone produced by the gut and help control glucose and appetite.
g1 stresses that approval does not mean immediate availability in pharmacies or lower prices. Launch dates and prices have not yet been disclosed, although the larger number of products could increase competition.
The report also notes that a pen approved for diabetes is not automatically cleared for obesity, since indications and treatment regimens can vary.